4. Smith & Nephew – Sports Medicine, Trauma and Reconstruction
2018 revenue: $3.629 billion
Smith & Nephew’s knee implants business grew 3%, to more than $1 billion in 2018, and its hip implants business was up 2% to $613 million.
Officials at Smith & Nephew (NYSE:SNN) are excited about the company’s dual-mobility technology for hip implants, which they say protects against dislocation without compromising the device’s range of motion, CEO Namal Nawana said during a February earnings call transcribed by Seeking Alpha.
London-based Smith & Nephew used the AAOS meeting in Las Vegas in March to introduce Navio 7.0, the latest software for its hand-held robotic surgical system. Expected to launch during the second half of 2019, the Navio 7.0 will include a new intuitive interface, expanded surgical preferences and streamlined workflow that may reduce surgery time. It’ll include hip software acquired through Smith & Nephew’s purchase of Brainlab’s orthopedic joint reconstruction business.
“We are a very relevant part of the overall robotic placements and units in the world today,” Nawana said of Navio.
Smith & Nephew in recent years has bolted on new technologies through acquisitions, including Rotation Medical and its regenerative shoulder repair treatment, and Ceterix Orthopaedics and its NovoStitch Pro knee repair device.